Leaps by Bayer

Leaps by Bayer operates as the corporate venture capital arm of the global life science company Bayer AG, dedicated to investing in breakthrough innovations that address some of the world's most pressing challenges in health and nutrition. Established with a mandate to foster radical advancements, Leaps by Bayer focuses on areas such as biotechnology, agriculture, and other scientific breakthroughs that align with its "10 Leaps" — ambitious goals like curing cancer, preventing cardiovascular disease, and enabling sustainable agriculture. Their investment philosophy emphasizes long-term commitment and significant capital deployment into companies with the potential for transformative impact.

The firm typically engages with companies from Series A onwards, providing substantial initial capital to fuel their growth and development. Leaps by Bayer's initial investments generally range from €5 million to €30 million, demonstrating their capacity to back promising ventures with meaningful cheques. Beyond the initial infusion, they are prepared to provide follow-on funding, with the potential to invest up to €100 million or more over the lifetime of a single portfolio company. This flexible and substantial funding approach allows them to support companies through multiple stages of their evolution, from early-stage research to market entry.

Since its inception, Leaps by Bayer has demonstrated a robust commitment to its mission. The firm has already committed over €1.6 billion in capital to more than 60 companies globally, building a diverse portfolio of innovative enterprises. Their portfolio includes companies working on cell and gene therapies, precision agriculture, microbiome research, and novel drug discovery platforms. By leveraging Bayer's extensive scientific expertise, global network, and regulatory knowledge, Leaps by Bayer offers its portfolio companies not just financial capital but also strategic support and access to invaluable resources, accelerating their path to market and impact.